Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model ...

Two new studies on NEFECON® demonstrate its treatment benefit in the 'Treat Early' strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: 'Treat the ...